Shenzhen Salubris Biomedical Engineering Co., Ltd. announced that it will receive CNY 310 million in an equity round of funding on December 12, 2021. The transaction will include participation from returning investor Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE:002294) and will retain it's 100% stake in the company. The transaction has been approved in the investor's eighth meeting of the fifth board of directors.